
    
      Part A (SAD):

      In Part A, subjects will receive a single dose of study drug, and the safety and efficacy of
      DD01 will be evaluated in overweight/obese subjects with T2DM.

      Part B (MAD):

      In Part B, subjects will receive once-weekly doses of the study drug for 4 weeks, and the
      safety and efficacy of DD01 will be evaluated in overweight/obese subjects with T2DM and
      NAFLD.
    
  